The medical-products maker’s shares tumbled after its quarterly profit and sales underwhelmed investors.

Shares of Abbott Laboratories plunged 10.04% to $108.61 Thursday, on what proved to be an all-around great trading session ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Laboratories (ABT) stock falls as underperformance in the company's Nutrition segment leads it to record lower than expected Q4 sales. Read more here.

School is back in session for the pupils and teachers of Abbott Elementary. Here's what to know after the midseason hiatus, including where to stream.

ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are forecast to come in at $1.50 a share. That compares with adjusted earnings of $1.34 a share a year earlier. REVENUE: Quarterly ...

Abbott's fourth quarter revenue missed expectations in its devices, diagnostics and nutrition segments, while staying in line for its established pharmaceutical business.

Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.